SGLT2 inhibitors reduced the risk of the 3P-MACE by 18% (S2 Fig) in patients with stage 3/4 CKD (HR 0.82, [95% CI 0.72–0.93], I2 = 37.47%). Here, SLC5A2 is linked to chronic kidney disease.